1. Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution
- Author
-
David A. Robinson, Claire L. Nunns, Christopher J. Northfield, Jonathan D. Moore, Christine M. Richardson, Ben Davis, James Brooke Murray, Victoria Oldfield, Pawel Dokurno, Simon F. Scrace, Lisa Baker, Stuart C. Ray, Christophe Fromont, Allan E. Surgenor, Natalia Matossova, Andrew John Potter, and Christopher J. Bryant
- Subjects
Models, Molecular ,Stereochemistry ,Clinical Biochemistry ,Cell ,Pharmaceutical Science ,Isomerase ,Biochemistry ,chemistry.chemical_compound ,Drug Discovery ,medicine ,Humans ,Imidazole ,Threonine ,NIMA-Interacting Peptidylprolyl Isomerase ,Molecular Biology ,Molecular Structure ,Kinase ,Drug discovery ,Organic Chemistry ,Imidazoles ,Peptidylprolyl Isomerase ,medicine.anatomical_structure ,chemistry ,PIN1 ,Molecular Medicine ,Caco-2 Cells - Abstract
Pin1 is an emerging oncology target strongly implicated in Ras and ErbB2-mediated tumourigenesis. Pin1 isomerizes bonds linking phospho-serine/threonine moieties to proline enabling it to play a key role in proline-directed kinase signalling. Here we report a novel series of Pin1 inhibitors based on a phenyl imidazole acid core that contains sub-μM inhibitors. Compounds have been identified that block prostate cancer cell growth under conditions where Pin1 is essential.
- Published
- 2010